Search Results 11-20 of 21359 for anti-TNF drugs

  1. Etanercept-Ykro (Subcutaneous Route) Description and Brand Names - Mayo Clinic

    Etanercept-ykro injection is used alone or together with other medicines (eg, methotrexate) to reduce signs and symptoms of active arthritis, rheumatoid ...

  2. Crohn's disease - Diagnosis and treatment - Mayo Clinic

    Infliximab (Remicade), adalimumab (Humira) and certolizumab pegol (Cimzia). Also known as TNF inhibitors, these drugs work by neutralizing an immune system ...

  3. Treatment response and management of biologics in patients with ECD - Mayo Clinic

    These include tumor necrosis factor-alpha (TNFα) inhibitors (certolizumab, infliximab, adalimumab), anti-integrin agents (vedolizumab, natalizumab), and ...

  4. Clinical Trials - Division of Infectious Diseases

    However, many CD and UC patients still ultimately require surgery despite the use of these medications. Side effects of the anti-TNF agents include increased ...

  5. Etanercept-Szzs (Subcutaneous Route) Description and Brand Names - Mayo Clinic

    Etanercept-szzs injection is used alone or with other medicines (eg, methotrexate) to reduce signs and symptoms of rheumatoid arthritis or psoriatic arthritis, ...

  6. Ankylosing spondylitis - Diagnosis & treatment - Mayo Clinic

    If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't helpful, your doctor might suggest starting a tumor necrosis factor (TNF) blocker or an interleukin-17 ( ...

  7. Ulcerative Colitis Clinical Trials - Mayo Clinic Research

    ... medications such as the anti-Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ...

  8. Ulcerative colitis - Diagnosis and treatment - Mayo Clinic

    Biologics · Infliximab (Remicade), adalimumab (Humira) and golimumab (Simponi). These medications, called tumor necrosis factor (TNF) inhibitors, work by ...

  9. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  10. A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) - Mayo Clinic

    ... treatment with anti-TNF-alpha agents. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...